TABLE 2.

Associations of olanzapine daily dose with weight changes as primary outcome

		5 mg olanzapine daily dose increase		High dose of olanzapine a
		E (95% CI)	p value	E (95% CI)	p‐value
Olanzapine dose	5 mg/day increase	0.03 (−0.07 to 0.12)	0.62
	High dose a			0.31 (0.07 to 0.55)	0.01
Age		−0.06 (−0.28 to 0.17)	0.63	−0.06 (−0.29 to 0.17)	0.63
Sex b		−0.23 (−1.04 to 0.58)	0.58	−0.24 (−1.05 to 0.57)	0.56
Baseline BMI		−0.20 (−0.28 to −0.13)	<0.001	−0.20 (−0.28 to −0.13)	<0.001
Smoking status c		0.46 (−0.24 to 1.16)	0.20	0.43 (−0.27 to 1.13)	0.23
Olanzapine treatment duration		1.98 (1.85 to 2.12)	<0.001	1.96 (1.82 to 2.09)	<0.001
In‐ vs. outpatient treatment		0.10 (−0.42 to 0.62)	0.71	0.11 (−0.41 to 0.63)	0.68
Co‐medication with
Lipid‐lowering agent		−1.59 (−2.32 to −0.87)	<0.001	−1.57 (−2.30 to −0.85)	<0.001
Hypertensive agent		0.76 (0.18 to 1.34)	0.01	0.77 (0.19 to 1.36)	0.01
Antidiabetic agent		0.11 (−1.37 to 1.58)	0.89	0.10 (1.37 to 1.57)	0.89
Second antipsychotic		−0.31 (−0.64 to 0.03)	0.076	−0.29 (−0.63 to 0.05)	0.09
Third antipsychotic		1.61 (1.14 to 2.08)	<0.001	1.62 (1.16 to 2.09)	<0.001
Antidepressant		0.78 (0.37 to 1.18)	<0.001	0.77 (0.37 to 1.18)	<0.001
Benzodiazepine		0.68 (0.39 to 0.98)	<0.001	0.68 (0.38 to 0.97)	<0.001

Note: Significant p‐values are indicated in bold.

Abbreviations: BMI, body mass index (kg/m²); CI, confidence interval; E, effect size.

^a High dose defined as >10 mg/day. A 5‐mg increase of olanzapine dose would correspond to a decreased 0.2 kg/m² of baseline BMI, increased 2 days of olanzapine treatment duration, decreased 1.59‐ and 0.31‐fold co‐prescription rates of lipid‐lowering agents and second antipsychotic and increased 0.76‐, 1.61‐, 0.78‐ and 0.68‐fold co‐prescription rates of hypertensive, third antipsychotic, antidepressants and benzodiazepines, respectively.

^b Males using females as reference.

^c Smokers using non‐smokers as reference.